EverGlade Consulting Archives - EverGlade Consulting

EverGlade Consulting

EverGlade Consulting

Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors

By Madison Fichtner, Operations Manager and Eric Jia-Sobota, Founder  The Defense Advanced Research Projects Agency is hosting an Industry Day for the B-SAFE (Broad-Spectrum Antagonists for Editors) program on June 28, 2024, in Arlington, VA, with a webinar option available. This event is pivotal for those in the science and technology communities, including industry, academia, […]

Join DARPA’s B-SAFE Industry Day for Groundbreaking Advances in Gene Editing Inhibitors Read More »

EverGlade Consulting

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease

At EverGlade Consulting, we are always on the lookout for new funding opportunities that can help our clients advance their research and development goals. Today, we’re excited to inform you about a new Request for Applications (RFA) from the National Institutes of Health (NIH): RFA-HG-24-004.

New NIH Funding Opportunity – Investigating the Role of Genomic Variation on Gene Regulation and Disease Read More »

EverGlade Consulting

EverGlade Funding Alert – BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D 

The Biomedical Advanced Research and Development Authority (BARDA) has recently unveiled significant updates to its Broad Agency Announcement (BAA), emphasizing a more refined and responsive approach to public health preparedness. Amendment 3, in particular, brings crucial changes to the Areas of Interest (AOIs) that are designed to align BARDA’s efforts with the evolving landscape of global health threats. 

EverGlade Funding Alert – BARDA Issues Amendment 3 to BAA for Medical Countermeasures R&D  Read More »

A New Valley of Death? by Eric Jia-Sobota

It seems that there may be a new Valley of Death on the horizon of COVID therapeutic development. Earlier this month (9 JUL) NIAID posted a Funding Opportunities Announcement soliciting proposals related to COVID therapeutic development through their Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program (RFA-AI-21-050: Antiviral Drug Discovery (AViDD) Centers

A New Valley of Death? by Eric Jia-Sobota Read More »

COVID-19 Antiviral Therapeutics Procurement by Eric Jia-Sobota

Earlier this month the Army Contracting Command published an amendment to solicitation W911QY-20-S-C001 related to Area of Interest 5, oral antiviral therapeutics. This is a procurement solicitation and specifically the USG is looking for direct-acting antivirals for COVID-19 high-risk patients. Successful offerors will be able to deliver 500,000 treatment courses of the anti-viral within eight

COVID-19 Antiviral Therapeutics Procurement by Eric Jia-Sobota Read More »

New Opportunity for COVID Therapeutics by Eric Jia-Sobota

For the past 18 months companies have been confused and frustrated by the shifting USG policies regarding the development of therapeutics as part of the COVID-19 response. BARDA was back and forth as parts of the BAA were suspended, unsuspended, and resuspended. The American rescue Plan legislation was passed about six months ago and although

New Opportunity for COVID Therapeutics by Eric Jia-Sobota Read More »

ACC-JCRD seeking Commercial Solutions by Eric Jia-Sobota

The Joint Army Contracting Command and the Joint COVID Response Division (ACC-JCRD) recently published a solicitation seeking Commercial Solutions to decrease US reliance on fragile global supply chains and increase preparedness for future pandemics. The solicitation seeks to establish, expand, and accelerate the availability of domestically-produced supplies in several different areas, some of which may

ACC-JCRD seeking Commercial Solutions by Eric Jia-Sobota Read More »

BARDA Funding Freeze Risks Companies Abandoning COVID Therapeutic Work

Executive Summary BARDA’s suspension of funding for COVID-19 therapeutics risks repeating mistakes of past pandemics as it may cause industry to pull out of the development space, experts say. Industry sources are concerned the Biden administration is focusing on funding NIH at the expense of BARDA. The Biomedical Advanced Research and Development Authority quietly suspended

BARDA Funding Freeze Risks Companies Abandoning COVID Therapeutic Work Read More »

CEPI Funding Opportunity by Eric Jia-Sobota

Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) published a call for proposals that is open from 28 JAN 2021 to 28 MAY 2021 and can be found here [CEPICfPCallText.pdf]. Trials that expand access in low and middle income countries is strongly encouraged. The objective is to expand access to vaccines that are already in

CEPI Funding Opportunity by Eric Jia-Sobota Read More »

BARDA Opportunities: Therapeutics by Eric Jia-Sobota

Recently BARDA published information about the COVID programs the USG is supporting through collaboration between HHS and DoD. Some of that information is summarized in the  table below. In the rush to respond to the COVID pandemic the portfolio became unbalanced, especially regarding therapeutics. With the new administration there is interest and funding available to

BARDA Opportunities: Therapeutics by Eric Jia-Sobota Read More »

Scroll to Top